100% of multiple myeloma patients respond to Janssen’s investigational CAR T therapy, data shows

pharmafile | May 14, 2020 | News story | Research and Development CAR T, CAR-T, Janssen, multiple myeloma, pharma 

Janssen has revealed new Phase1b/2 findings of the efficacy of its investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, known as JNJ-4528, in the treatment of relapsed or refractory multiple myeloma

The company reported that the findings revealed a 100% response rate among participants to the therapy, and this breaks down into 97% achieving a “very good partial response or better” and 3% achieving a partial response. Evaluated participants had previously received a median of five treatment regimens, with 86% of them triple-refractory while 28% were penta-refractory.

The data further showed that, median time to response was one month, and after a median follow-up of 11.5 months, 86% of patients receiving the therapy achieved stringent complete response, while 86% of patients were alive and free of disease progression at nine months.

However, it was also noted that 100% of patients experienced the adverse event neutropenia, while 93% experienced cytokine release syndrome.

“These recently updated data from the CARTITUDE-1 study suggest a durable response and tolerable safety profile for JNJ-4528,” commented Dr Sen Zhuang, Vice President, Oncology Clinical Development at Janssen. “We continue to advance the investigation of this novel CAR-T treatment with the goal of bringing a differentiated immunotherapy to patients with multiple myeloma, many of whom have exhausted all potential prior treatment options.”

The promising findings are to be followed by longer-term follow-up data from the Phase1b portion of the study, which is due to be presented at the American Society of Clinical Oncology (ASCO) Virtual Scientific Program, Janssen confirmed.

Matt Fellows

Related Content


Janssen CLL treatment combination sees success in trials

Janssen has announced positive data from its Phase III GLOW study, with the combination of …

NICE recommends Janssen’s active psoriatic arthritis drug

NICE have released a Final Appraisal Document (FAD) recommending Janssen’s tremfya (guselkumab) as a new …


Janssen sees promising PRO data for prostate cancer therapy

Janssen has announced patient-reported outcomes (PRO) data from the pre-specified final analysis of their Phase …

Latest content